Financial Data and Key Metrics Changes - The company reported a total of 8,569,338 shares of common stock issued and outstanding as of the record date [7] - A quorum was established with more than half of the outstanding shares present at the meeting [8] Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were provided in the meeting records Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The meeting included proposals for the election of directors and the ratification of the independent registered public accounting firm, indicating ongoing governance and compliance efforts [10][11] - The company proposed an amendment to increase the number of shares authorized for issuance under the equity incentive plan, suggesting a focus on incentivizing management and employees [11] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The meeting was conducted virtually, allowing shareholders to vote online [4] - The results of the voting will be disclosed in a current report on Form 8-K within four business days [13] Q&A Session All Questions and Answers Question: Were there any shareholder questions during the meeting? - No questions were submitted by shareholders during the meeting [14]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 reached $10.2 million, a 42% increase compared to $7.2 million in Q2 2024, aligning with previous guidance of 40% to 50% growth [14][5] - Gross margin improved to 78.3% from 73.2% year-over-year, reflecting reduced production costs and strategic pricing [14][16] - Operating income was $1.9 million, slightly down by $100,000 from the previous year, while net income decreased to $1.1 million from $6.6 million due to lower non-cash gains [15][16] Business Line Data and Key Metrics Changes - Sold 116 Ultramist systems in Q2, marking a 61% increase year-over-year and an 18% increase from Q1 [5] - Applicator revenue constituted $6.4 million, representing 63% of overall revenues, with a 37% year-over-year growth [6][14] - Customer concentration decreased, with only one customer exceeding 5% of revenues [6] Market Data and Key Metrics Changes - The company is focusing on expanding awareness and adoption of Ultramist, particularly in wound care centers, nursing homes, and hospitals [11][33] - There is a noted increase in inbound inquiries, indicating a potential adoption threshold has been crossed [10][11] Company Strategy and Development Direction - The company is transitioning to a new applicator design aimed at increasing production capacity and reducing costs, expected to impact margins positively in early 2026 [7][26] - A concerted outbound marketing campaign is planned for October, targeting specific wound types and customer segments [10][33] - The company is also enhancing its sales infrastructure, having fully staffed its national sales territories for the first time [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's progress and the potential for sustainable, profitable growth [13][17] - The company is cautious about Q3 guidance due to tough comparisons from the previous year but remains focused on disciplined execution [18][19] Other Important Information - The company is moving to a new office space to accommodate growth, indicating operational expansion [20] - The company holds a significant patent portfolio, which is seen as a core asset for future growth and potential monetization opportunities [51] Q&A Session Summary Question: Impact of new production process on gross margin - Management expects to gain 350 to 400 basis points of additional margin from the new applicator design, with gradual impact starting in early 2026 [24][26] Question: Sales team adequacy - Management feels confident in the current sales team but is open to adding more representatives as needed [29][31] Question: Marketing program focus - The marketing program will target specific wound types and customer segments, aiming to build trust and awareness in the market [33] Question: Update on senior secured debt - The company is in the process of refinancing its debt and has received attractive term sheets, indicating a significant improvement over current terms [37][38] Question: Pipeline for large accounts - Management highlighted recent additions to the approved vendor list of a large hospital chain, indicating potential for significant sales growth [44][45] Question: Value of patent portfolio - The company has a large patent portfolio related to Shockwave and ultrasound technologies, which is seen as a core asset for operations and potential monetization [50][51]

Q2 FY2025 August 8, 2025 Live Presentation Friday, August 8, 2025, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1723341&tp_key=b9f972bf82 Replay Dial-in Information Toll Free: 1-844-512-2921 or 1-412-317-6671 Replay Pin Number: 11159256 Replay Expiry: August 29, 2025 2 Forward Looking Statements and Non-GAAP Financial M ...

Exhibit 99.1 Sanuwave Announces Q2 FY2025 Financial Results Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for Q3 2025. EDEN PRAIRIE, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to Commission File Number 000-52985 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 20-1176000 (Sta ...

Company Overview - Sanuwave Health, Inc. is a leading provider of next-generation FDA-approved wound care products focused on research, development, and commercialization of patented, non-invasive medical systems for tissue repair and regeneration [1][2][3] - The company applies its patented energy transfer technologies in various medical fields including wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions [3] Financial Results Announcement - Sanuwave will host a live conference call on August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results [1] - Access to the call can be made via toll-free and international numbers, with a specific conference ID provided for participants [1] Replay Information - A replay of the conference call will be available until August 29, 2025, with specific toll-free and international numbers for access [2]

Core Viewpoint - Sanuwave Health, Inc. is set to present at the 45th Annual Canaccord Genuity Growth Conference, highlighting its position as a leading provider of next-generation, FDA-approved wound care products [1][2]. Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [3]. - The company offers an end-to-end wound care portfolio that includes regenerative medicine products designed to restore the body's normal healing processes [4]. Conference Details - The group presentation is scheduled for August 13, 2025, from 9:30 to 9:55 a.m. ET, with opportunities for one-on-one meetings with investors available throughout the conference [2].

Core Insights - Sanuwave Health, Inc. reported preliminary revenues of $10.1 million to $10.2 million for Q2 2025, marking the highest quarterly revenues in the company's history [1][2] - The revenue for Q2 2025 reflects an increase of 41% to 42% compared to Q2 2024, while the first half of 2025 saw a revenue increase of 50% to 51% compared to the first half of 2024 [1][2] Company Developments - The CEO highlighted that the first half of 2025 has been a transition period for the company, with the addition of a new head of sales and a new head of commercial operations [3] - The company is expanding its sales team, reaching 13 salespeople and covering all national sales territories for the first time under the current CEO [3] - A national accounts manager has been added to pursue larger market opportunities, indicating a strategic focus on growth [3] Future Outlook - The company plans to release full Q2 results around August 8, 2025, providing a more comprehensive update on performance and future plans [3] - Sanuwave is focused on the research, development, and commercialization of patented, non-invasive medical systems aimed at tissue repair and regeneration [4] - The company's portfolio includes regenerative medicine products that support normal healing processes across various medical conditions [5]

Group 1 - The article discusses the experience of an investor who began trading during the pandemic and emphasizes the importance of analyzing earnings reports to identify potential growth stocks [1] - The investor successfully identified several future winners, including OPRX, OTRK, FUBO, and PLUG, by focusing on key information from earnings transcripts and reports [1]

Libby brings strong team building, growth, and sales operations and systems skills to Sanuwave after a career of growing startups into mid- and large-sized companies.EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations. Libby brings 20 years of medical device experience focused on com ...